PL2590645T3 - Związki karbaminianowe do leczenia zaburzenia dwubiegunowego - Google Patents

Związki karbaminianowe do leczenia zaburzenia dwubiegunowego

Info

Publication number
PL2590645T3
PL2590645T3 PL11801093T PL11801093T PL2590645T3 PL 2590645 T3 PL2590645 T3 PL 2590645T3 PL 11801093 T PL11801093 T PL 11801093T PL 11801093 T PL11801093 T PL 11801093T PL 2590645 T3 PL2590645 T3 PL 2590645T3
Authority
PL
Poland
Prior art keywords
bipolar disorder
carbamate compounds
treating bipolar
treating
carbamate
Prior art date
Application number
PL11801093T
Other languages
English (en)
Inventor
Sung James Lee
Susan Marie Melnick
Original Assignee
Sk Biopharmaceuticals Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sk Biopharmaceuticals Co., Ltd. filed Critical Sk Biopharmaceuticals Co., Ltd.
Publication of PL2590645T3 publication Critical patent/PL2590645T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/223—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of alpha-aminoacids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL11801093T 2010-06-30 2011-06-27 Związki karbaminianowe do leczenia zaburzenia dwubiegunowego PL2590645T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12/827,505 US9610274B2 (en) 2010-06-30 2010-06-30 Methods for treating bipolar disorder
PCT/KR2011/004676 WO2012002687A2 (en) 2010-06-30 2011-06-27 Methods for treating bipolar disorder
EP11801093.3A EP2590645B1 (en) 2010-06-30 2011-06-27 Carbamate compounds for treating bipolar disorder

Publications (1)

Publication Number Publication Date
PL2590645T3 true PL2590645T3 (pl) 2018-03-30

Family

ID=45400168

Family Applications (1)

Application Number Title Priority Date Filing Date
PL11801093T PL2590645T3 (pl) 2010-06-30 2011-06-27 Związki karbaminianowe do leczenia zaburzenia dwubiegunowego

Country Status (13)

Country Link
US (2) US9610274B2 (pl)
EP (1) EP2590645B1 (pl)
JP (1) JP5881692B2 (pl)
KR (1) KR101828934B1 (pl)
CN (1) CN102985085B (pl)
AU (1) AU2011272156B2 (pl)
BR (1) BR112012033738A2 (pl)
CA (1) CA2801241C (pl)
ES (1) ES2654615T3 (pl)
MX (2) MX360030B (pl)
PL (1) PL2590645T3 (pl)
RU (1) RU2653408C2 (pl)
WO (1) WO2012002687A2 (pl)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1890684T3 (pl) 2005-06-08 2014-05-30 Sk Biopharmaceuticals Co Ltd Leczenie zaburzeń snu i czuwania
US8741950B2 (en) 2009-06-22 2014-06-03 Sk Biopharmaceuticals Co., Ltd. Methods for treating or preventing fatigue
TWI684450B (zh) 2013-03-13 2020-02-11 南韓商愛思開生物製藥股份有限公司 猝倒症之治療
EP3021838B1 (en) 2013-07-18 2020-05-27 Jazz Pharmaceuticals Ireland Limited Treatment for obesity
US10888542B2 (en) 2014-02-28 2021-01-12 Sk Biopharmaceuticals Co., Ltd. Aminocarbonylcarbamate compounds
TWI655179B (zh) 2014-02-28 2019-04-01 南韓商愛思開生物製藥股份有限公司 胺基羰基胺基甲酸酯化合物
DK3509582T3 (en) 2016-09-06 2024-02-12 Axsome Malta Ltd Solvatform af (r)-2-amino-3-phenylpropylcarbamat
US10195151B2 (en) 2016-09-06 2019-02-05 Jazz Pharmaceuticals International Iii Limited Formulations of (R)-2-amino-3-phenylpropyl carbamate
EP4316592A3 (en) 2016-10-06 2024-05-01 Axsome Malta Ltd. Carbamoyl phenylalaninol compounds and uses thereof
AU2017374458B2 (en) * 2016-12-14 2023-03-02 Sk Biopharmaceuticals Co., Ltd. Use of carbamate compounds for prevention, alleviation or treatment of bipolar disorder
WO2018222954A1 (en) 2017-06-02 2018-12-06 Jazz Pharmaceuticals International Iii Limited Methods and compositions for treating excessive sleepiness
AU2018312328B2 (en) 2017-07-31 2022-12-15 Jazz Pharmaceuticals Ireland Limited Carbamoyl phenylalaninol analogs and uses thereof
US10940133B1 (en) 2020-03-19 2021-03-09 Jazz Pharmaceuticals Ireland Limited Methods of providing solriamfetol therapy to subjects with impaired renal function

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ314570A (en) 1993-06-10 2000-11-24 Lilly Co Eli Treatment of emesis using tetrahydrobenz[cd]indole-6-carboxamides
KR100197892B1 (ko) 1994-09-09 1999-06-15 남창우 신규한 페닐알킬아미노 카바메이트 화합물과 그의 제조방법
US5756817C1 (en) 1995-02-11 2001-04-17 Sk Corp O-carbamoyl-phenylananinol compounds their pharmaceutically useful salts and process for preparing the same
KR0173862B1 (ko) 1995-02-11 1999-04-01 조규향 O-카바모일-(d)-페닐알라닌올 화합물과 그의 약제학적으로 유용한 염 및 이들의 제조방법
IT1275903B1 (it) 1995-03-14 1997-10-24 Boehringer Ingelheim Italia Esteri e ammidi della 1,4-piperidina disostituita
KR0173863B1 (ko) 1995-04-10 1999-04-01 조규향 페닐에 치환체가 있는 o-카바모일-페닐알라닌올 화합물과 그의 약제학적으로 유용한 염 및 이들의 제조방법
WO1998015526A1 (en) 1996-10-10 1998-04-16 Sk Corporation O-carbamoyl-phenylalaninol compounds, their pharmaceutically useful salts and process for preparing the same
WO1998017636A1 (en) 1996-10-22 1998-04-30 Ortho Pharmaceutical Corporation Phenylalaninol derivatives for the treatment of central nervous system disorders
TW548103B (en) 1997-07-11 2003-08-21 Janssen Pharmaceutica Nv Bicyclic benzamides of 3- or 4-substituted 4-(aminomethyl)-piperidine derivatives
PT1076055E (pt) 1998-04-28 2005-02-28 Dainippon Pharmaceutical Co Derivados de 1-[ (1-substituido-4-piperidinil)-metil]-4-piperidina, processo para a sua preparacao, composicoes medicinais que os contem e intermediarios destes compostos
US20010029262A1 (en) 1998-06-29 2001-10-11 Sethi Kapil Dev Method of treatment or prophylaxis
TW518218B (en) 1999-05-27 2003-01-21 Merck Patent Gmbh Pharmaceutical compositions comprising 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl)piperazine or its physiologically acceptable salts for use in the treatment of sub-type anxiety disorders
US20010034320A1 (en) 2000-01-18 2001-10-25 Hans-Michael Brecht NK1-receptor antagonists for treating restless legs syndrome
EP1347971B1 (en) 2000-12-21 2006-03-01 Bristol-Myers Squibb Company Thiazolyl inhibitors of tec family tyrosine kinases
RS67603A (en) 2001-02-27 2007-02-05 Ortho-Mcneil Pharmaceutical Inc., Carbamate compounds for use in the treatment of pain
CN1262272C (zh) 2001-02-27 2006-07-05 奥索-麦克尼尔药品公司 用于预防或治疗运动障碍的氨基甲酸酯化合物
CA2443108A1 (en) 2001-04-03 2002-10-17 Merck & Co. Inc. N-substituted nonaryl-heterocyclo amidyl nmda/nr2b antagonists
JP2004537526A (ja) 2001-06-12 2004-12-16 メルク　エンド　カムパニー　インコーポレーテッド 片頭痛の治療又は予防用ｎｒ２ｂ受容体拮抗薬
US20040115263A1 (en) 2002-08-26 2004-06-17 Robertson David W. Use of bupropion for treating restless legs syndrome
AU2003259482A1 (en) 2002-09-20 2004-04-08 Pfizer Japan Inc. N-substituted piperidinyl-imidazopyridine compounds as 5-ht4 receptor modulators
BRPI0409592A (pt) 2003-04-21 2006-05-02 Pfizer compostos imidazopiridina tendo atividade agonìstica do receptor 5-ht4 e atividade antagonìstica do receptor 5-ht3
RS20060145A (en) 2003-09-03 2008-06-05 Pfizer Inc., Benzimidazolone compounds having 5-ht4 receptor agonistic activity
US20050080268A1 (en) 2003-10-08 2005-04-14 Yong-Moon Choi Process of preparing O-carbamoyl compounds in the presence of active amine group
EP1548011A1 (en) 2003-12-23 2005-06-29 Neuro3D Benzo[1,4]diazepin-2-one derivatives as phosphodiesterase PDE2 inhibitors, preparation and therapeutic use thereof
WO2005092882A1 (en) 2004-03-01 2005-10-06 Pfizer Japan, Inc. 4-amino-5-halogeno-benzamide derivatives as 5-ht4 receptor agonists for the treatment of gastrointestinal, cns, neurological and cardiovascular disorders
AU2005302589B2 (en) * 2004-10-28 2010-09-16 Sk Biopharmaceuticals Co., Ltd. Adjunctive therapy for depression
JP4193949B2 (ja) 2005-04-08 2008-12-10 ファイザー・プロダクツ・インク Ｉ型グリシン輸送阻害剤としての二環式［３．１．０］ヘテロアリールアミド
US7598279B2 (en) 2005-04-22 2009-10-06 Sk Holdings Co., Ltd. Neurotherapeutic azole compounds
PL1890684T3 (pl) 2005-06-08 2014-05-30 Sk Biopharmaceuticals Co Ltd Leczenie zaburzeń snu i czuwania
EP1893291B1 (en) 2005-06-22 2010-03-03 SK Holdings Co., Ltd. Treatment of sexual dysfunction
WO2007018496A1 (en) 2005-07-26 2007-02-15 Janssen Pharmaceutica, N.V. Methods for treating substance-related disorders
EP1754476A1 (en) 2005-08-18 2007-02-21 Schwarz Pharma Ag Lacosamide (SPM 927) for treating myalgia, e.g. fibromyalgia
KR20090082213A (ko) 2006-10-13 2009-07-29 얀센 파마슈티카 엔.브이. 페닐알킬아미노 카바메이트 조성물
HUP0700370A2 (en) * 2007-05-24 2009-04-28 Richter Gedeon Nyrt Use of (thio)-carbamoyl-cyclohexane derivatives in the manufacture of a medicament for the treatment of acute mania
US8642772B2 (en) 2008-10-14 2014-02-04 Sk Biopharmaceuticals Co., Ltd. Piperidine compounds, pharmaceutical composition comprising the same and its use
US8741950B2 (en) 2009-06-22 2014-06-03 Sk Biopharmaceuticals Co., Ltd. Methods for treating or preventing fatigue
US8232315B2 (en) 2009-06-26 2012-07-31 Sk Biopharmaceuticals Co., Ltd. Methods for treating drug addiction and improving addiction-related behavior
KR101097605B1 (ko) 2009-11-04 2011-12-22 알.에프 에이치아이씨 주식회사 도허티 증폭기
RU2556585C2 (ru) 2009-11-06 2015-07-10 Ск Биофармасъютиклс Ко., Лтд. Способы лечения синдрома дефицита внимания и гиперактивности
CN102781436B (zh) 2009-11-06 2014-01-08 爱思开生物制药株式会社 纤维肌痛综合征的治疗方法
US8623913B2 (en) 2010-06-30 2014-01-07 Sk Biopharmaceuticals Co., Ltd. Methods for treating restless legs syndrome

Also Published As

Publication number Publication date
KR101828934B1 (ko) 2018-03-29
EP2590645B1 (en) 2017-10-04
AU2011272156A1 (en) 2013-02-07
MX2012014686A (es) 2013-02-11
BR112012033738A2 (pt) 2017-08-08
MX360030B (es) 2018-10-19
US20170151209A1 (en) 2017-06-01
RU2012155118A (ru) 2014-08-10
WO2012002687A2 (en) 2012-01-05
KR20130112706A (ko) 2013-10-14
US20120004300A1 (en) 2012-01-05
CA2801241A1 (en) 2012-01-05
EP2590645A2 (en) 2013-05-15
EP2590645A4 (en) 2014-01-22
ES2654615T3 (es) 2018-02-14
AU2011272156B2 (en) 2015-02-12
WO2012002687A3 (en) 2012-04-26
CN102985085A (zh) 2013-03-20
CA2801241C (en) 2018-07-17
JP2013533253A (ja) 2013-08-22
US9907777B2 (en) 2018-03-06
US9610274B2 (en) 2017-04-04
RU2653408C2 (ru) 2018-05-08
JP5881692B2 (ja) 2016-03-09
CN102985085B (zh) 2018-10-02

Similar Documents

Publication Publication Date Title
PL2590645T3 (pl) Związki karbaminianowe do leczenia zaburzenia dwubiegunowego
HK1216902A1 (zh) 用作治療肌肉萎縮的改進外顯子跳躍組合物
EP2875824A4 (en) COMPOSITION FOR THE PREVENTION OR TREATMENT OF CACHEXIA
IL253421B (en) Compounds for the treatment of fibrosis (Leifat)
IL225623A0 (en) Psoriasis treatment methods
HK1200459A1 (en) Modified creatine compounds
HK1199616A1 (en) Cachexia treatment
GB201010359D0 (en) Compounds for treating proliferative disorders
ZA201503005B (en) Ingenol-derived compounds useful for treating cancer
EP2536282A4 (en) METHOD FOR THE TREATMENT OF INFECTIONS
HK1179954A1 (en) Quinazoline compounds
ZA201209270B (en) Mixture for treating fertilizers
EP2704731A4 (en) TREATMENT OF AVIAN ORIGIN
EP2563353A4 (en) COMPOUNDS FOR ANTIFUNGAL TREATMENT
GB201120594D0 (en) Catalyst compounds
GB201116328D0 (en) Treatment for tumours
IL213610A0 (en) Composition for treating dermatological conditions
GB201009495D0 (en) Compounds for treating proliferative disorders
GB201019034D0 (en) Treatment for tumors
GB201000771D0 (en) Compound for therapy
GB201118482D0 (en) Treating tumours
EP2740724A4 (en) COMPOUND FOR TREATING CARTILAGE DISORDERS
GB201015971D0 (en) Cure for epilepsy
GB201102267D0 (en) Treatment
GB201102270D0 (en) Treatment